4939-28-0Relevant articles and documents
The Ag-promoted α-C-H arylation of alcohols
Wang, Shoufeng,Xing, Shuya,Zhang, Yingying,Fan, Yafei,Zhao, Huaiqing,Wang, Jianfeng,Zhang, Shuxiang,Wang, Wengui
, p. 41847 - 41850 (2019)
We herein report the functionalization of α-C-H in alcohols through cross-dehydrogenative coupling reactions. Selectfluor was used as a mild oxidant. In situ-generated HF participated in the reaction and no external strong acid was necessary. A variety of heteroaryl-substituted alcohols were achieved with good yields and with good functional group tolerance.
Preparation method of 2-methyl-4-hydroxymethyl quinoline and derivatives thereof
-
Paragraph 0015; 0017; 0029-0038, (2019/06/07)
The invention belongs to the technical field of chemical synthesis, and particularly relates to a method for reacting 2-methylquinoline and derivatives thereof with primary alcohol. The method is carried out by the following steps of: under the catalysis of Selectfluor/AgNO3, reacting the 2-methylquinoline and the derivatives in a primary alcohol aqueous solution, and performing column chromatography to obtain a product of dehydrogenation coupling of 4-position and alcohol compounds of the 2-methylquinoline derivatives. The method provided by the invention is carried out in a mixed solution ofwater and alcohol compounds under the catalysis of Selectfluor/AgNO3, and has the advantages of good substrate solubility, wide applicability, high reaction yield and strong controllability. The method is green and environment-friendly, and has the advantages of few side reaction products, green and high efficiency.
Quinoline substituted chalcone compound as well as preparation method and application thereof
-
, (2019/03/29)
The invention discloses a novel quinoline substituted chalcone compound as well as pharmaceutically acceptable salts and a preparation method thereof. The invention further discloses a pharmaceuticalcomposition which comprises a therapeutically effective amount of the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts and a pharmaceutically acceptable carrier. The invention further discloses a tubulin inhibitor which comprises the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts. The invention further disclosesapplication of the novel quinoline substituted chalcone compound and/or the pharmaceutically acceptable salts in preparing drugs for treating but not limited to colon cancer, leukemia, liver cancer, breast cancer and other diseases. The compound in the application shows excellent anti-tumor activity, and has more stable metabolic properties and better druggability prospect.